Eupraxia Pharmaceuticals (EPRX) Receivables - Net (2022 - 2025)

Eupraxia Pharmaceuticals (EPRX) has 4 years of Receivables - Net data on file, last reported at $716095.0 in Q4 2025.

• On a quarterly basis, Receivables - Net rose 177.48% year-over-year to $716095.0 in Q4 2025; TTM through Dec 2025 was $716095.0, a 177.48% increase from a year earlier, with the FY2025 full-year figure at $716095.0, up 177.48% from the prior year.
• Receivables - Net for Q4 2025 stood at $716095.0, up from $258074.0 in the prior quarter.
• Over the last five years, Receivables - Net for EPRX reached as high as $716095.0 in Q4 2025 and fell as low as $13892.0 in Q4 2022.
• Historically, Receivables - Net has averaged $285452.5 across 4 years, with a median of $205911.5 in 2023.
• Across the five-year window, Receivables - Net jumped 1006.74% in 2023 and surged 67.85% in 2024, its largest moves.
• Year by year, Receivables - Net stood at $13892.0 in 2022, then soared by 1006.74% to $153749.0 in 2023, then surged by 67.85% to $258074.0 in 2024, then soared by 177.48% to $716095.0 in 2025.
• Per Business Quant data, the three most recent Receivables - Net figures were $716095.0 in Q4 2025, $258074.0 in Q4 2024, and $153749.0 in Q4 2023.